Canadapiet I just want to correct you on one things. Velosbio is not a preclinical company. They were bought Nov2020 and Oct2020 they started their Ph2. So the price tag is for a company that has basically finished the clinical trial THTX is just about to start. They have their dose, their initial safety data and their initial efficacy data. The data set is small but strong
https://www.merck.com/news/merck-to-acquire-velosbio/
They are also developing a bi-specific antibody based on their IP. That's another very hot sector of cancer drug development. Essentially you have one antibody that targets T-cells and one that targets cancer cells that are joined together and so you force the two cell types to come together and get the T-cells to do their thing without first having to develop a cancer specific response. I don't know if it's possible but it wouldn't be a terrible thing for THTX to explore an antibody/peptide conjugate that did the same thing targeting sortilin. I might believe they were an ideas machine if they did something like that.